依诺肝素每日一次与每日两次用于急性静脉血栓栓塞初始治疗的比较
基于RIETE注册数据比较急性静脉血栓栓塞患者使用依诺肝素每日两次与每日一次在15天和30天的结局。倾向性评分分析显示每日一次组大出血和死亡更少,但30天VTE复发更多。
要点
- 每日一次依诺肝素组较每日两次组大出血和死亡更少。
- 30天时每日一次组VTE复发更多(OR 2.5,95%CI 1.03-5.88)。
- 倾向性评分分析显示每日一次组大出血和死亡风险更低。
核心结论
- 研究结果证实,每日一次依诺肝素较每日两次导致更少的大出血,与对照临床试验的Meta分析提示一致。
研究设计与样本
- 使用RIETE注册数据比较接受依诺肝素每日两次与每日一次患者的15天和30天VTE复发、大出血和死亡发生率,并采用倾向性评分匹配校正混杂变量。
- 研究纳入4730例患者:3786例(80%)接受依诺肝素每日两次,944例每日一次。
主要发现
- 前15天,每日一次组较每日两次组VTE复发有增多趋势(OR 1.79;95%CI 0.55-5.88),大出血更少(OR 0.42;95%CI 0.17-1.08),死亡更少(OR 0.32;95%CI 0.13-0.78)。
- 第30天,每日一次组较每日两次组VTE复发更多(OR 2.5;95%CI 1.03-5.88),大出血更少(OR 0.40;95%CI 0.17-0.94),死亡更少(OR 0.58;95%CI 0.33-1.00)。
- 倾向性分析中,每日一次组较每日两次组15天(HR 0.30;95%CI 0.10-0.88)和30天(HR 0.16;95%CI 0.04-0.68)大出血更少,15天(HR 0.37;95%CI 0.14-0.99)和30天(HR 0.19;95%CI 0.07-0.54)死亡也更少。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials In venous thromboembolism (VTE), it is uncertain if enoxaparin should be given twice or once daily. We compared the 15- and 30-day outcomes in VTE patients on enoxaparin twice vs. once daily. Patients on enoxaparin once daily had fewer major bleeds and deaths than those on twice daily. The rate of VTE recurrences was similar in both subgroups. SUMMARY: Background In patients with acute venous thromboembolism (VTE), it is uncertain whether enoxaparin should be administered twice or once daily. Methods We used the RIETE Registry data to compare the 15- and 30-day rates of VTE recurrence, major bleeding and death between patients receiving enoxaparin twice daily and those receiving it once daily. We used propensity score matching to adjust for confounding variables. Results The study included 4730 patients: 3786 (80%) received enoxaparin twice daily and 944 once daily. During the first 15 days, patients on enoxaparin once daily had a trend towards more VTE recurrences (odds ratio [OR], 1.79; 95% confidence interval [CI], 0.55-5.88), fewer major bleeds (OR, 0.42; 95% CI, 0.17-1.08) and fewer deaths (OR, 0.32; 95% CI, 0.13-0.78) than those on enoxaparin twice daily. At day 30, patients on enoxaparin once daily had more VTE recurrences (OR, 2.5; 95% CI, 1.03-5.88), fewer major bleeds (OR, 0.40; 95% CI, 0.17-0.94) and fewer deaths (OR, 0.58; 95% CI, 0.33-1.00). On propensity analysis, patients on enoxaparin once daily had fewer major bleeds at 15 (hazard ratio [HR], 0.30; 95% CI, 0.10-0.88) and at 30 days (HR, 0.16; 95% CI, 0.04-0.68) and also fewer deaths at 15 (HR, 0.37; 95% CI, 0.14-0.99) and at 30 days (HR, 0.19; 95% CI, 0.07-0.54) than those on enoxaparin twice daily. Conclusions Our findings confirm that enoxaparin prescribed once daily results in fewer major bleeds than enoxaparin twice daily, as suggested in a meta-analysis of controlled clinical trials.
引用
- Trujillo-Santos J, Bergmann JF, Bortoluzzi C, et al. Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. J Thromb Haemost. 2017. PMID: 28120516. doi:10.1111/jth.13616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。